GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence

M Brunetti, I Shemilt, S Pregno, L Vale… - Journal of clinical …, 2013 - Elsevier
OBJECTIVES: In this article, we describe how to include considerations about resource
utilization when making recommendations according to the Grading of Recommendations …

Econometric issues in prospective economic evaluations alongside clinical trials: combining the nonparametric bootstrap with methods that address missing data

A Jalali, RM Tamimi, SM McPherson… - Epidemiologic …, 2022 - academic.oup.com
Prospective economic evaluations conducted alongside clinical trials have become an
increasingly popular approach in evaluating the cost-effectiveness of a public health …

Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11

AW Dick, RL Pacula, AJ Gordon, M Sorbero… - Health …, 2015 - healthaffairs.org
Opioid use disorders are a significant public health problem, affecting two million people in
the United States. Treatment with buprenorphine, methadone, or both is predominantly …

Supply of buprenorphine waivered physicians: the influence of state policies

BD Stein, AJ Gordon, AW Dick, RM Burns… - Journal of substance …, 2015 - Elsevier
Buprenorphine, an effective opioid use disorder treatment, can be prescribed only by
buprenorphine-waivered physicians. We calculated the number of buprenorphine-waivered …

Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials

MGW Dijkgraaf, BP van der Zanden, CAJM de Borgie… - Bmj, 2005 - bmj.com
Objective To determine the cost utility of medical co-prescription of heroin compared with
methadone maintenance treatment for chronic, treatment resistant heroin addicts. Design …

Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013

RM Burns, RL Pacula, S Bauhoff, AJ Gordon… - Substance …, 2016 - journals.sagepub.com
Background State Medicaid policies play an important role in Medicaid enrollees' access to
and use of opioid agonists, such as methadone and buprenorphine, in the treatment of …

Drug treatment as HIV prevention: a research update

DS Metzger, GE Woody, CP O'Brien - JAIDS Journal of Acquired …, 2010 - journals.lww.com
Drug use continues to be a major factor fueling the global epidemic of HIV infection. This
article reviews the current literature on the ability of drug treatment programs to reduce HIV …

ABCB1 genetic variability and methadone dosage requirements in opioid‐dependent individuals

JK Coller, DT Barratt, K Dahlen… - Clinical …, 2006 - Wiley Online Library
Background and Objectives The most common treatment for opioid dependence is
substitution therapy with another opioid such as methadone. The methadone dosage is …

Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder

B Enns, E Krebs, DGT Whitehurst… - Drug and Alcohol …, 2023 - Elsevier
Background Our objective was to examine the cost-effectiveness of flexible take-home
buprenorphine-naloxone (BNX) versus methadone alongside the OPTIMA trial in Canada …

Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a …

D Otiashvili, G Piralishvili, Z Sikharulidze… - Drug and alcohol …, 2013 - Elsevier
Aims Determine the extent to which buprenorphine injectors continue treatment with
buprenorphine-naloxone or methadone, and the impact of these treatments on substance …